FOR IMMEDIATE RELEASE

HUNTSVILLE, Ala. - Serina Therapeutics, Inc., will introduce a late-breaking abstract at the Movement Disorder Society annual meeting in Dublin, Ireland on June 20. The abstract presents promising results for the treatment of Parkinson’s disease. Serina Therapeutics is a pharmaceutical research and development company located at the HudsonAlpha Institute for Biotechnology.

Randall Moreadith, M.D., Ph.D., president and chief executive officer for Serina Therapeutics, will outline the work in a special session at noon on June 20th. “We have developed a polymer conjugate that may be given as a single weekly dose in a standard insulin syringe using our proprietary POZ polymer platform.”

Moreadith added the work represents a novel approach to deliver continuous dopaminergic stimulation to patients with Parkinson’s disease. “This is a long-sought therapeutic strategy that may offset many of the complications of prolonged dopamine therapy in patients with Parkinson’s disease.”

He said the company’s polyoxazoline platform has advanced to two major unmet medical needs-- patients with cancer and patients with debilitating neurological disease. “We are very excited to extend our polymer platform to the development of subcutaneous small molecule therapeutics that may address a host of potential diseases,” said Moreadith.

The presentation is available on Serina’s website – www.serinatherapeutics.com.

About Serina
Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs. Serina Therapeutics is located at the HudsonAlpha Institute for Biotechnology in Huntsville, Ala.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com